CD5-positive B cell subsets in secondary progressive multiple sclerosis.

Masaaki Niino, Toshiyuki Fukazawa, Naoya Minami, Itaru Amino, Jun Tashiro, Naoto Fujiki, Shizuki Doi, Seiji Kikuchi

Department of Clinical Research, Hokkaido Medical Center, Yamanote 5-jo 7-chome, Sapporo 063-0005, Japan. niino@hok-mc.hosp.go.jp

Neuroscience letters 2012 Aug 8

filter terms:

Previous studies have demonstrated that CD5(+) B cells produce more interleukin (IL)-10 than CD5(-) B cells and that CD5(+) B cells confer significant protection against experimental autoimmune encephalomyelitis (EAE). The objective of the present study was to determine whether CD5-positive B cell populations are associated with secondary progressive multiple sclerosis (SPMS) and to explore which subsets on CD5(+) B cells are associated with SPMS. A total of 26 patients with SPMS, of whom 11 were treated with IFNβ (IFN-SPMS) and 15 were not treated (non-IFN-SPMS), and 19 healthy control (HC) subjects were included in the study. Expression levels of CD11a, CD23, CD25, CD38, CD49d, CD80, CD86, CD138, CCR5, and CXCR5 on CD5(+) B cells in blood samples were examined by flow cytometry. The percentage of CD5(+) B cells in the SPMS group was significantly lower than in the HC group. Within the subsets of CD5(+) B cells, the expression of CD11a in the non-IFN-SPMS group was significantly decreased compared to the HC subjects. Patients with SPMS showed lower CCR5, CD25, and CD138 positivity on CD5(+) B cells than HC subjects. Our results indicate that CD5(+) B cell subsets might be associated with pathogenesis of SPMS. Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Citation

Masaaki Niino, Toshiyuki Fukazawa, Naoya Minami, Itaru Amino, Jun Tashiro, Naoto Fujiki, Shizuki Doi, Seiji Kikuchi. CD5-positive B cell subsets in secondary progressive multiple sclerosis. Neuroscience letters. 2012 Aug 8;523(1):56-61